Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Atropine Oxide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 6/20 | 0.80 |
| ▸ | CHRM5 known ✓ | P08912 | 5/20 | 0.75 |
| ▸ | CHRM1 known ✓ | P11229 | 5/20 | 0.75 |
| ▸ | CHRM3 known ✓ | P20309 | 5/20 | 0.75 |
| ▸ | CHRM4 known ✓ | P08173 | 4/20 | 0.75 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.63 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.63 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.63 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.98 |
| ▸ | BLM | P54132 | 4/20 | 0.78 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.78 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.76 |
| ▸ | MEN1 | O00255 | 3/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.75 |
| ▸ | TSHR | P16473 | 2/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.65 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Atropine Oxide SCHEMBL1490299 | 0.99 | CYP2C19 (0.95) | CYP2C19CHRM2BLMPABPC1SMN1; SMN2 | |
| Atropine Oxide SCHEMBL1490302 | 0.99 | CYP2C19 (0.95) | CYP2C19CHRM2BLMPABPC1SMN1; SMN2 | |
| Atropine Oxide SCHEMBL162929 | 0.99 | CYP2C19 (1.00) | CYP2C19CHRM2BLMPABPC1SMN1; SMN2 | |
| Atropine Oxide SCHEMBL29369999 | 0.99 | CYP2C19 (1.00) | CYP2C19CHRM2BLMPABPC1SMN1; SMN2 | |
| Atropine Oxide SCHEMBL98985 | 0.99 | CYP2C19 (1.00) | CYP2C19CHRM2BLMPABPC1SMN1; SMN2 | |
| Methylatropine SCHEMBL34463463 | 0.89 | CHRM2 (1.00) | CYP2C19CHRM2BLMPABPC1SMN1; SMN2 | |
| Methylatropine SCHEMBL824874 | 0.89 | CHRM2 (1.00) | CYP2C19CHRM2BLMPABPC1SMN1; SMN2 | |
| Methylatropine SCHEMBL1321572 | 0.88 | BLM (1.00) | CYP2C19CHRM2BLMPABPC1SMN1; SMN2 | |
| Methylatropine SCHEMBL30647266 | 0.88 | BLM (1.00) | CYP2C19CHRM2BLMPABPC1SMN1; SMN2 | |
| Methylatropine SCHEMBL29389879 | 0.88 | PABPC1 (1.00) | CYP2C19CHRM2BLMPABPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240335378-A1 | COMPOSITIONS AND METHODS FOR TREATING SIALORRHEA | UNIV UTAH RES FOUND (US) | 2024-10-10 | — | — | US | claimed |
| US-20240335378-A1 | COMPOSITIONS AND METHODS FOR TREATING SIALORRHEA | UNIV UTAH RES FOUND (US) | 2024-10-10 | — | — | US | disclosed |
| EP-4426302-A1 | COMPOSITIONS AND METHODS FOR TREATING SIALORRHEA | University of Utah Research Foundation (US) | 2024-09-11 | — | — | EP | disclosed |
| US-12048763-B2 | Compositions and methods for treating sialorrhea | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2024-07-30 | — | — | US | disclosed |
| US-20230149306-A1 | COMPOSITIONS AND METHODS FOR TREATING SIALORRHEA | UNIVERSITY OF UTAH RESEARCH FOUNDATION | 2023-05-18 | — | — | US | disclosed |
| WO-2023076698-A1 | COMPOSITIONS AND METHODS FOR TREATING SIALORRHEA | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2023-05-04 | — | — | WO | disclosed |
| WO-2022211996-A1 | LIPOPHILIC ACTIVE AGENT INFUSED TOBACCO LEAVES AND/OR TOBACCO MATERIALS AND METHODS OF USE THEREOF | Poviva Corp. (US) | 2022-10-06 | — | — | WO | disclosed |
| US-20210289832-A1 | LIPOPHILIC ACTIVE AGENT INFUSED TOBACCO LEAVES AND/OR TOBACCO MATERIALS AND METHODS OF USE THEREOF | Poviva Corp. (US) | 2021-09-23 | — | — | US | disclosed |
| US-20210290771-A1 | ENGINEERED RECEPTOR/LIGAND SYSTEM FOR DELIVERY OF THERAPEUTIC AGENTS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2021-09-23 | — | — | US | disclosed |
| EP-3849347-A1 | LIPOPHILIC ACTIVE AGENT INFUSED TOBACCO LEAVES AND/OR TOBACCO MATERIALS AND METHODS OF USE THEREOF | Poviva Corp. (US) | 2021-07-21 | — | — | EP | disclosed |
| EP-1163011-A2 | FATTY ACID-ANTICANCER CONJUGATES AND USES THEREOF | Protarga Inc. (US) | 2001-12-19 | — | — | EP | disclosed |
| US-6267957-B1 | Attaching agents to tissue with transglutaminase and a transglutaminase substrate | PERICOR SCIENCE, INC. | 2001-07-31 | — | — | US | disclosed |
| US-20010002404-A1 | Fatty acid-pharmaceutical agent conjugates | LUITPOLD PHARMACEUTICALS, INC. | 2001-05-31 | — | — | US | disclosed |
| WO-2001007009-A1 | LYSINE OXIDASE LINKAGE OF AGENTS TO TISSUE | PERICOR SCIENCE, INC. (US) | 2001-02-01 | — | — | WO | disclosed |
| WO-2001006829-A2 | LINKAGE OF AGENTS TO TISSUE | PERICOR SCIENCE, INC. (US) | 2001-02-01 | — | — | WO | disclosed |
| EP-1054998-A1 | TRANSGLUTAMINASE LINKAGE OF AGENTS TO TISSUE | Pericor Science, Inc. (US) | 2000-11-29 | — | — | EP | disclosed |
| WO-2000053231-A2 | FATTY ACID-ANTICANCER CONJUGATES AND USES THEREOF | PROTARGA, INC. (US) | 2000-09-14 | — | — | WO | disclosed |
| WO-1999036570-A2 | TRANSGLUTAMINASE LINKAGE OF AGENTS TO TISSUE | PERICOR SCIENCE INC (US) | 1999-07-22 | — | — | WO | disclosed |
| WO-1999030690-A1 | ORAL DELIVERY FORMULATION | AXIA THERAPEUTICS, INC. (US) | 1999-06-24 | — | — | WO | disclosed |
| US-5795909-A | ANTICARCINOGENIC AND ANTITUMOR AGENTS; BREAST, COLON, OVARIANCANCERS | NEUROMEDICA, INC. (US) | 1998-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010002404-A1 | Fatty acid-pharmaceutical agent conjugates | FABP7, FFAR2, FFAR4 | CHRM2 2104/4885CHRM5 1909/4885CHRM1 3136/4885 |
| US-20240335378-A1 | COMPOSITIONS AND METHODS FOR TREATING SIALORRHEA | ACHE, MUC1, NEU3 | CHRM2 24/4885CHRM5 30/4885CHRM1 134/4885 |
| US-20230149306-A1 | COMPOSITIONS AND METHODS FOR TREATING SIALORRHEA | ACHE, MUC1, NEU3 | CHRM2 24/4885CHRM5 30/4885CHRM1 134/4885 |
| US-12048763-B2 | Compositions and methods for treating sialorrhea | ACHE, NEU3, AMY2A | CHRM2 14/4885CHRM5 19/4885CHRM1 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.